Google
AZTR Stock Price & Analysis — Azitra Inc (Healthcare >> Biotechnology)
AZTR FAQ
What is AZTR's ROE?
Azitra Inc reports a Return on Equity (ROE) of -112.73%.
What is AZTR's dividend yield?
Azitra Inc offers a dividend yield of 0.00%.
What is AZTR's Quality Score?
Our AI rates AZTR's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AZTR?
Our AI Timing Score for AZTR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AZTR belong to?
Azitra Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange
AZTR AI Analysis Summary
Our AI summary for AZTR: Azitra Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -112.73%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.14
Price
0.00
(0.80%)
Day Change
|
|
|---|
AZTR, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 70 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.14 |
| PBV / Sector |
0.21 / 44,105.10
GREAT
|
| Earning Per Share | -0.74 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.24 M
GREAT
|
| Average 1W Daily Value |
0.43 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:40 |
| Symbol | AZTR |
| Name | AZITRA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 16.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2.23 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 21 Business Park Drive, Branford, CT, United States, 06405
Phone: 203 646 6446
Website: https://azitrainc.com
Sector: Healthcare >> Biotechnology
Description: Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap